The International Journal of Neuropsychopharmacology
April 17, 2023
Shokouh Arjmand, Marie Vadstrup Pedersen, N. Silva et al.
Abstract Background Recent preclinical and clinical studies have shed light on the possible impact of sex and estrous/menstrual cycle on ketamine’s antidepressant action but with incongruous results. The preclinical studies that have shown the effects of ovarian sex hormones have not done so in animal models of depression. Thus, the aim of the present study is to scrutinize the acute behavioral...
JAMA Oncology
April 13, 2023
Manish Agrawal, Ezekiel Emanuel, Brian D. Richards et al.
48 citations
This nonrandomized controlled trial used a 1-to-1 therapist-to-patient ratio to administer psilocybin to groups of patients with cancer who were diagnosed with major depression disorder to create a scalable, rapidly effective depression treatment.
Advanced Healthcare Materials
April 8, 2023
Jing Ge, Ronghua Tan, Qian Gao et al.
Ketamine (KA), commonly used as an anesthetic, is now widely studied as an antidepressant for the treatment of depression. However, due to its side effects, such as addiction and cognitive impairment, the dosage and frequency of (S)‐ketamine approved by the FDA for the treatment of refractory depression is very low, which limits its efficacy. Here, a new multifunctional nanocarrier system...
International Journal of Health Sciences
April 5, 2023
Luísa Soares Capa, Gabrielle Simon Tronco, Virginia Nascimento Reinert et al.
: Treatment-resistant depression is a common psychiatric disorder that can lead to significant disability and decreased quality of life for patients. In recent years, there has been growing interest in the combination of intravenous ketamine and electroconvulsive therapy (ECT) for the treatment of treatment-resistant depression. Ketamine is an anesthetic that is an N-methyl-D-aspartate (NMDA)...
The Journal of Clinical Psychiatry
April 5, 2023
Albert Yeung, Guy Sapirstein, Laura D Crain et al.
Although consensus in the field is lacking, the most common definition for treatment-resistant depression (TRD) requires a minimum of 2 prior treatment failures with confirmed adequate dose and duration. This article presents a clinical example of TRD in a patient with a long history of depression and inadequate response to treatment. The prominent feature is the patient's persistent...
Current Psychology
April 1, 2023
Alan Maddock, Carolyn Blair
Abstract: This study aimed to systematically review studies which conducted a controlled mediation analysis in order to examine the potential mechanisms which underlie mindfulness-based programme’s (MBPs) effects on anxiety, depression and psychological distress in any health or mental health population. Searches of six databases (Medline (Ovid), PsycINFO, Cochrane Central Register of...
Mindfulness
April 1, 2023
Isa Zappullo, Vincenzo Paolo Senese, Roberta Cecere et al.
Abstract: Objectives: Available data suggest that inflexible allocation of attention in people on the autism spectrum can lead to anxiety and depression symptoms, through the increase of repetitive negative thinking (worry and rumination). In the present study, we used dispositional mindfulness as a proxy to attention flexibility and tested its role in the influence of repetitive negative...
Mindfulness
April 1, 2023
Stella Kümmerle, Thomas Heidenreich, Meike Müller-Engelmann
Abstract Objectives Despite various methodological concerns, previous studies mainly use questionnaires to assess mindfulness. Following a multi-measurement approach, the present study aimed to evaluate the added value of an experience-sampling measure in the context of posttraumatic stress disorder (PTSD) and depression. Method Data were collected in a PTSD group, depression group, and control...
CNS Spectrums
April 1, 2023
Amanda Jones, Caroline Streicher, Shawn Alter et al.
AbstractBackgroundAXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational, NMDA receptor antagonist with multimodal activity being developed for MDD. The dextromethorphan component of AXS-05 is an NMDA receptor antagonist and a sigma-1 receptor agonist. The bupropion component of AXS-05 serves primarily to increase the bioavailability of dextromethorphan.MethodsAXS-05 was...
CNS Spectrums
April 1, 2023
Amanda Jones, Roger S McIntyre, Mark Jacobsen et al.
AbstractBackgroundTreatments for MDD that can improve both overall depressive and anhedonic symptoms are urgently needed.AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for MDD. The dextromethorphan component of AXS-05 is an NMDA receptor antagonist and a sigma-1 receptor agonist. The bupropion component of...
AJN, American Journal of Nursing
April 1, 2023
Diane S Aschenbrenner
Auvelity, an extended-release fixed combination of dextromethorphan and bupropion, is approved for the treatment of major depressive disorder in adults.Like all antidepressants, dextromethorphan-bupropion carries a boxed warning that it may increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Seizures can also occur and are more likely at higher doses.The...
Journal of Affective Disorders
April 1, 2023
Olivier Payette, Paul Lespérance, V. D. Jodoin et al.
7 citations
BACKGROUND For individuals with treatment-resistant depression (TRD), transcranial magnetic stimulation (TMS) has become a well-established approach. In the past decade, intravenous (IV) racemic ketamine has also emerged as a potential treatment for TRD. Currently, little data is available on the clinical effects of IV racemic ketamine in TRD patients who experienced TMS-failure. METHODS...
Pharmaceuticals
April 1, 2023
Aleksander Kwaśny, A. Włodarczyk, Damian Ogonowski et al.
27 citations
Background: Depression is a debilitating disease with a high socioeconomic burden. Regular antidepressants usually require several weeks to ameliorate symptoms; however, numerous patients do not achieve remission. What is more, sleep disturbances are one of the most common residual symptoms. Ketamine is a novel antidepressant with rapid onset of action with a proven antisuicidal effect. Little...
Journal of Affective Disorders
April 1, 2023
Artemis Zavaliangos-Petropulu, Shawn M. Mcclintock, Jacqueline Khalil et al.
16 citations
INTRODUCTION Ketamine treatment prompts a rapid antidepressant response in treatment-resistant depression (TRD). We performed an exploratory investigation of how ketamine treatment in TRD affects different cognitive domains and relates to antidepressant response. METHODS Patients with TRD (N = 66; 30 M/35F; age = 39.5 ± 11.1 years) received four ketamine infusions (0.5 mg/kg). Neurocognitive...
Psychopharmacology
April 1, 2023
David S. Mathai, Sandeep M. Nayak, David B. Yaden et al.
36 citations
The relationship between subjective drug experience and antidepressant outcomes for ketamine derivatives is poorly understood but of high clinical relevance. Esketamine is the patented (S)-enantiomer of ketamine and has regulatory approval for psychiatric applications. We examined the relationship between acute dissociation, as measured by the Clinician-Administered Dissociative States Scale...
Expert Review of Clinical Pharmacology
April 1, 2023
Jeffrey M. Witkin, Lalit K Golani, Jodi L Smith
18 citations
Deficiencies in standard of care antidepressants are driving novel drug discovery. A new age of antidepressant medications has emerged with the introduction of rapid-acting antidepressants with efficacy in treatment-resistant patients. The newly approved medicines and those in clinical development for major depressive disorder (MDD) are documented in this scoping review of newly approved and...
Neurochemical Research
April 1, 2023
Jared VanderZwaag, Torin Halvorson, Kira Dolhan et al.
25 citations
There is much excitement surrounding recent research of promising, mechanistically novel psychotherapeutics - psychedelic, anesthetic, and dissociative agents - as they have demonstrated surprising efficacy in treating central nervous system (CNS) disorders, such as mood disorders and addiction. However, the mechanisms by which these drugs provide such profound psychological benefits are still...
Frontiers in Psychiatry
March 31, 2023
Erik Ekbäck, Lina Rådmark, Gabriel Granåsen et al.
Background: Depression is a top-ranking global health concern increasing in magnitude. Available treatments for adolescents and young adults are not convincingly effective and relapse rates remain high. Training for Awareness, Resilience and Action (TARA) is a group treatment program targeting specific pathophysiological mechanisms of depression in young people. TARA is feasible, acceptable,...
Neuropsychiatric Disease and Treatment
March 31, 2023
Xu Chen, Xuan Hou, Daisy Bai et al.
Purpose: This Phase 3, multicenter study (NCT03434041) was conducted in primarily Chinese patients with treatment-resistant depression (TRD) to support the registration of esketamine nasal spray in China. Patients and methods: This randomized, double-blind, active-controlled study was conducted in China and the United States (US) in patients with TRD (single or recurrent episode). Eligible...
Behavioral Sciences
March 31, 2023
Jonathan Joseph Dawood Hristova, Virtudes Pérez-Jover
39 citations
Depression is a common mental health issue that affects 280 million people in the world with a high mortality rate, as well as being a leading cause of disability. Psychopharmacological therapies with psychedelics, particularly those with psilocybin, are showing promising potential for the treatment of depression, among other conditions. Some of their benefits include a rapid and exponential...